<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">COPD</journal-id><journal-id journal-id-type="iso-abbrev">COPD</journal-id><journal-id journal-id-type="archive">ICOP</journal-id><journal-id journal-id-type="publisher-id">icop20</journal-id><journal-title-group><journal-title>COPD</journal-title></journal-title-group><issn pub-type="ppub">1541-2555</issn><issn pub-type="epub">1541-2563</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27159613</article-id><article-id pub-id-type="pmc">5152596</article-id><article-id pub-id-type="publisher-id">1170111</article-id><article-id pub-id-type="doi">10.3109/15412555.2016.1170111</article-id><article-categories><subj-group subj-group-type="article-type"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wedzicha</surname><given-names>Jadwiga A.</given-names></name><xref ref-type="aff" rid="af0001">
<sup>a</sup>
</xref><xref ref-type="corresp" rid="an0001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Agusti</surname><given-names>Alvar</given-names></name><xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Donaldson</surname><given-names>Gavin</given-names></name><xref ref-type="aff" rid="af0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chuecos</surname><given-names>Ferran</given-names></name><xref ref-type="aff" rid="af0003">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lamarca</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="af0003">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garcia Gil</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="af0003">
<sup>c</sup>
</xref></contrib><aff id="af0001"><label><sup>a</sup></label><institution><named-content content-type="institution-name">Airways Disease Section, National Heart and Lung Institute, Imperial College London</named-content></institution>, <named-content content-type="city">London</named-content>, <country>UK</country></aff><aff id="af0002"><label><sup>b</sup></label><institution><named-content content-type="institution-name">Institut del T&#x000f2;rax, Hospital Cl&#x000ed;nic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias</named-content></institution>, <named-content content-type="city">Barcelona</named-content>, <country>Spain</country></aff><aff id="af0003"><label><sup>c</sup></label><institution><named-content content-type="institution-name">AstraZeneca R&#x00026;D Centre</named-content></institution>, <named-content content-type="city">Barcelona</named-content>, <country>Spain</country></aff></contrib-group><author-notes><corresp id="an0001">Jadwiga A. Wedzicha <email xlink:href="w.wedzicha@imperial.ac.uk">w.wedzicha@imperial.ac.uk</email><institution><named-content content-type="institution-name">Airways Disease Section, National Heart and Lung Institute, Imperial College London</named-content></institution>, Guy Scadding Building, Dovehouse Street, <named-content content-type="city">London</named-content><named-content content-type="postal-code">SW3 6LY</named-content>, <country>United Kingdom</country></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>11</month><year>2016</year><!--string-date: December 2016--></pub-date><pub-date pub-type="epub"><day>9</day><month>5</month><year>2016</year></pub-date><volume>13</volume><issue>6</issue><fpage seq="1">669</fpage><lpage>676</lpage><history><date date-type="received"><day>2</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="description"> &#x000a9; Jadwiga A. Wedzicha, Alvar Agusti, Gavin Donaldson, Ferran Chuecos, Rosa Lamarca, and Esther Garcia Gil. <copyright-statement>--><copyright-statement>&#x000a9; 2016 The Author(s). Published with license by Taylor &#x00026; Francis Group, LLC</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="icop-13-669.pdf"/><abstract><title>ABSTRACT</title><p>We investigated the effect of the long-acting muscarinic antagonist aclidinium bromide on chronic obstructive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled, parallel-group Phase III studies of 3&#x02013;6&#x000a0;months&#x02019; duration. Data were pooled from the aclidinium 400&#x000a0;&#x003bc;g twice-daily (BID) and placebo arms (<italic>N</italic>&#x000a0; = &#x000a0;2,521) and stratified by Global initiative for chronic Obstructive Lung Disease (GOLD) group (A, B, C and D). Results showed that fewer patients experienced &#x02265;1 exacerbation with aclidinium (any severity: 12.5%; moderate to severe: 10.9%) compared with placebo (any severity: 15.7%; moderate to severe: 13.3%) and the odds of experiencing &#x02265;1 exacerbation of any severity were reduced in patients receiving aclidinium (odds ratio&#x000a0; = &#x000a0; 0.78, <italic>p</italic>&#x000a0; = &#x000a0;0.039). Furthermore, aclidinium reduced the rate of exacerbations compared with placebo (any severity: rate ratio&#x000a0; = &#x000a0;0.79, <italic>p</italic>&#x000a0; = &#x000a0;0.026; moderate to severe: 0.80, <italic>p</italic>&#x000a0; = &#x000a0;0.044). The time to first exacerbation of any severity was delayed with aclidinium compared with placebo (hazard ratio&#x000a0; = &#x000a0;0.79, <italic>p</italic>&#x000a0; = &#x000a0;0.026) and there was a numerical delay in time to first moderate-to-severe exacerbation. Finally, the effects of aclidinium on exacerbations versus placebo were greater in patients in GOLD Groups B and D; however, it is of note that only 10.7% of patients were classified in Group A or C. In summary, the results indicate that aclidinium 400&#x000a0;&#x003bc;g BID reduces the frequency of COPD exacerbations compared with placebo and that these effects are greater in symptomatic patients.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>GOLD</kwd><kwd>long-acting muscarinic antagonist</kwd><kwd>symptoms</kwd></kwd-group><counts><fig-count count="5"/><table-count count="4"/><equation-count count="0"/><ref-count count="32"/><page-count count="8"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Exacerbations in patients with chronic obstructive pulmonary disease (COPD) are associated with an accelerated decline of lung function (<xref rid="cit0001" ref-type="bibr">1&#x02013;4</xref>), impaired health status (<xref rid="cit0005" ref-type="bibr">5&#x02013;7</xref>) and increased mortality <xref rid="cit0008" ref-type="bibr">(8)</xref>. Exacerbations of COPD, particularly those requiring hospitalizations, are a major contributor to the economic burden of COPD (<xref rid="cit0009" ref-type="bibr">9,10</xref>). The prevention of COPD exacerbations is an important longer-term goal of COPD therapy <xref rid="cit0011" ref-type="bibr">(11)</xref>.</p><p>Recent studies have provided evidence that long-acting muscarinic antagonists (LAMAs) can reduce the frequency of exacerbations versus placebo (<xref rid="cit0012" ref-type="bibr">12,13</xref>) or&#x02014;in a population enriched for exacerbations&#x02014;versus long-acting &#x003b2;<sub>2</sub>-agonists (LABAs) (<xref rid="cit0014" ref-type="bibr">14,15</xref>). Indeed, the 2014 Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines recommended LAMAs as maintenance therapy for patients with a high risk of exacerbation (&#x02265;2 exacerbations or &#x02265;1 exacerbation leading to hospitalization in the previous year, or severe airflow limitation [GOLD Stage III and IV]) and/or a high level of symptoms (GOLD Groups B, C and D) <xref rid="cit0011" ref-type="bibr">(11)</xref>.</p><p>Aclidinium bromide 400&#x000a0;&#x003bc;g is a twice-daily (BID) LAMA indicated as a maintenance therapy for patients with COPD <xref rid="cit0016" ref-type="bibr">(16)</xref>. Although exacerbations have been assessed in Phase III clinical studies of aclidinium and its combination with formoterol (<xref rid="cit0005" ref-type="bibr">5,17&#x02013;22</xref>), the individual studies were not designed to assess exacerbations as a primary endpoint. Here, we investigated the effect of aclidinium monotherapy on exacerbations using pooled data from five Phase&#x000a0;III studies of 3&#x02013;6&#x000a0;months&#x02019; duration. Additionally, we performed a novel exploratory analysis to assess the differential effect of aclidinium on exacerbations according to the GOLD Groups (A, B, C and D).</p></sec><sec sec-type="methods" id="s0002"><title>Methods</title><sec id="s0002-0001"><title>Study design</title><p>Data were pooled from the aclidinium 400&#x000a0;&#x003bc;g BID monotherapy and placebo arms of five studies in patients with moderate-to-severe COPD, of which three studies were designed to assess the efficacy and safety of aclidinium monotherapy (ACCORD I [NCT00891462], ACCORD II [NCT01045161] and ATTAIN [NCT01001494]), and two were designed to assess the efficacy and safety of aclidinium/formoterol combined (ACLIFORM [NCT01462942] and AUGMENT [NCT01437397]; <xref rid="t0001" ref-type="table">Table&#x000a0;1</xref>). All five studies were multinational, multicenter, randomized, double-blind and parallel-group in design. Detailed methods of each study have been published elsewhere (<xref rid="cit0005" ref-type="bibr">5,17&#x02013;20,22</xref>). Aclidinium 400&#x000a0;&#x003bc;g and placebo were administered in the morning and evening via a breath-actuated multidose dry powder inhaler (Genuair&#x02122;/Pressair<sup>&#x000ae;</sup>
<xref ref-type="fn" rid="en0001">
<sup>1</sup>
</xref>).
<table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1. </label><caption><p>Study designs.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="45pt" align="left"/><col width="53pt" align="left"/><col width="33pt" align="left"/><col width="68pt" align="left"/><col width="40pt" align="left"/></colgroup><thead><tr><th align="left">Study name</th><th align="center">ClinicalTrials.gov registration</th><th align="center">Treatment weeks</th><th align="center">Treatment arms</th><th align="center">Randomized patients</th></tr></thead><tbody><tr><td colspan="5" align="left">Monotherapy</td></tr><tr><td align="left">&#x02003;ACCORD I</td><td align="left">NCT00891462</td><td align="center">12</td><td align="left">Aclidinium 400&#x000a0;&#x003bc;g BID, Aclidinium 200&#x000a0;&#x003bc;g BID, Placebo</td><td align="center">561</td></tr><tr><td align="left">&#x02003;ACCORD II</td><td align="left">NCT01045161</td><td align="center">12</td><td align="left">Aclidinium 400&#x000a0;&#x003bc;g BID, Aclidinium 200&#x000a0;&#x003bc;g BID, Placebo</td><td align="center">544</td></tr><tr><td align="left">&#x02003;ATTAIN</td><td align="left">NCT01001494</td><td align="center">24</td><td align="left">Aclidinium 400&#x000a0;&#x003bc;g BID, Aclidinium 200&#x000a0;&#x003bc;g BID, Placebo</td><td align="center">828</td></tr><tr><td colspan="5" align="left">Combination therapy</td></tr><tr><td align="left">&#x02003;ACLIFORM</td><td align="left">NCT01462942</td><td align="center">24</td><td align="left">Aclidinium/formoterol 400/12&#x000a0;&#x003bc;g BID, Aclidinium/formoterol 400/6&#x000a0;&#x003bc;g BID, Aclidinium 400&#x000a0;&#x003bc;g BID, Formoterol 12&#x000a0;&#x003bc;g BID, Placebo</td><td align="center">1,729</td></tr><tr><td align="left">&#x02003;AUGMENT</td><td align="left">NCT01437397</td><td align="center">24</td><td align="left">Aclidinium/formoterol 400/12&#x000a0;&#x003bc;g BID, Aclidinium/formoterol 400/6&#x000a0;&#x003bc;g BID, Aclidinium 400&#x000a0;&#x003bc;g BID, Formoterol 12&#x000a0;&#x003bc;g BID, Placebo</td><td align="center">1,692</td></tr></tbody></table><table-wrap-foot><fn><p>BID, twice-daily.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="s0002-0002"><title>Patients</title><p>Male and female patients aged &#x02265;40&#x000a0;years who were current or former smokers (&#x02265;10&#x000a0;pack-years) with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1&#x000a0;second [FEV<sub>1</sub>] &#x02265;30% and &#x0003c;80% predicted and FEV<sub>1</sub>/FVC ratio &#x0003c;70%) were eligible for inclusion in the studies. A history of &#x02265;1 exacerbation was not an inclusion criterion. Exclusion criteria included presence or history of clinically significant respiratory disease (other than COPD) or cardiovascular conditions, respiratory infection or COPD exacerbation &#x02264;6&#x000a0;weeks pre-screening and hospitalization for COPD exacerbation &#x02264;3&#x000a0;months pre-screening.</p><p>Inhaled salbutamol (100&#x000a0;&#x003bc;g/puff) was permitted as relief medication, provided its use was discontinued 6&#x000a0;hours prior to study visits. Inhaled corticosteroids (ICS), oral or parenteral corticosteroids (equivalent to &#x02264;10&#x000a0;mg/day of prednisone or 20&#x000a0;mg every other day), oral sustained-release methylxanthines and oxygen therapy (&#x0003c;15&#x000a0;hours/day) were allowed, provided treatment was stable &#x02265;4&#x000a0;weeks pre-screening. Other long-acting bronchodilators were prohibited.</p><p>Study protocols were approved by all necessary ethics committees. All patients provided written informed consent.</p></sec><sec id="s0002-0003"><title>Assessment of exacerbations</title><p>COPD exacerbations were assessed by the investigator using the Healthcare Resource Utilization definition (an increase of COPD symptoms during &#x02265;2&#x000a0;consecutive days that required a change in COPD treatment). Exacerbations were categorized as mild (self-managed by the patient at home by increasing usual COPD medication [short-acting bronchodilator and/or ICS use]), moderate (did not lead to hospitalization, but were treated with antibiotics and/or systemic corticosteroids or an increase in dose of systemic corticosteroids) or severe (led to hospitalization [overnight stay or emergency room visit]). A COPD exacerbation was considered a new exacerbation episode if the patient had not taken oral steroids and antibiotics for &#x02265;14&#x000a0;days since the previous exacerbation.</p></sec><sec id="s0002-0004"><title>Statistical analysis</title><p>Individual data were pooled from the aclidinium monotherapy and placebo arms of the intent-to-treat (ITT) population (all patients who received at least one dose of the study medication and had a baseline and at least one post-baseline FEV<sub>1</sub> assessment) in each study. Exacerbation rates were annualized by dividing the number of exacerbations by the number of days the patient participated and multiplying by 365.25.</p><p>For analyses of exacerbation rates and time to first exacerbation, data were stratified according to the GOLD COPD assessment (Groups A, B, C and D) based on level of symptoms (St. George's Respiratory Questionnaire [SGRQ] total score &#x0003c;25 [Groups A and C] or &#x02265;25 [Groups B and D] <xref rid="cit0023" ref-type="bibr">(23)</xref>), airflow limitation severity (GOLD Stage I or II vs. III or IV) and previous exacerbation history (&#x02264;1&#x000a0;vs. &#x02265;2 within the previous year) <xref rid="cit0024" ref-type="bibr">(24)</xref>. For further analysis, patients were also pooled by level of symptoms (low [Group A+C] vs. high [Group B+D]). Data were also stratified by baseline ICS use for analyses of exacerbation rates.</p><p>Whether or not patients experienced &#x02265;1 COPD exacerbation was analyzed based on a logistic regression model with treatment group, study, smoking status and baseline airflow limitation severity as factors. The number of COPD exacerbations was analyzed using a negative binomial regression model with the total number of COPD exacerbations as response. Exposure time was included as an offset. Time to first exacerbation was analyzed using a Cox proportional hazard model, with time from first study dose to failure (an exacerbation) right censored by study termination (withdrawal or study end &#x02013; whichever occurred first). Both models included age, treatment group, study, sex, baseline ICS use, baseline airflow limitation severity and smoking status as covariates.</p></sec></sec><sec sec-type="results" id="s0003"><title>Results</title><sec id="s0003-0001"><title>Patients</title><p>In total, 2,521 patients were included<xref rid="t0002" ref-type="table">
<sup>Table 2</sup>
</xref> in the pooled analysis (ITT population). Patient demographics and baseline characteristics were similar across the five studies, although ATTAIN and ACLIFORM had a higher proportion of male patients and AUGMENT had fewer patients with &#x02265;1 exacerbation in the 12&#x000a0;months prior to study entry (<xref rid="t0002" ref-type="table">Table&#x000a0;2</xref>). Overall, 28.3% of patients had experienced &#x02265;1 exacerbation in the previous year (<xref rid="t0002" ref-type="table">Table&#x000a0;2</xref>). The majority of patients were classified in GOLD Groups B (41.4%) and D (47.9%; <xref rid="f0001" ref-type="fig">Figure&#x000a0;1</xref>). Most patients in GOLD Group D were classified as such due to a FEV<sub>1</sub> lower than 50% of the reference. ICS use was similar between treatment groups in each study. Overall, 39.5% of patients in the placebo group and 38.3% of patients in the aclidinium group were using concomitant ICS (<xref rid="f0002" ref-type="fig">Figure&#x000a0;2</xref>).
<table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2. </label><caption><p>Patient demographics and baseline characteristics (ITT population).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt" align="left"/><col width="35pt" align="left"/><col width="35pt" align="left"/><col width="35pt" align="left"/><col width="35pt" align="left"/><col width="35pt" align="left"/><col width="60pt" align="left"/><col width="50pt" align="left"/><col width="30pt" align="left"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th align="center">ACCORD I</th><th align="center">ACCORD II</th><th align="center">ATTAIN</th><th align="center">ACLIFORM</th><th align="center">AUGMENT</th><th align="center">Pooled placebo arms</th><th align="center">Pooled aclidinium 400&#x000a0;&#x003bc;g BID arms</th><th align="center">Overall</th></tr></thead><tbody><tr><td align="left">Number of patients</td><td align="center">375<xref rid="t2fn0001" ref-type="fn">
<sup>a</sup>
</xref></td><td align="center">359<xref rid="t2fn0001" ref-type="fn">
<sup>a</sup>
</xref></td><td align="center">542<xref rid="t2fn0001" ref-type="fn">
<sup>a</sup>
</xref></td><td align="center">577<xref rid="t2fn0001" ref-type="fn">
<sup>a</sup>
</xref></td><td align="center">668<xref rid="t2fn0001" ref-type="fn">
<sup>a</sup>
</xref></td><td align="center">1,165</td><td align="center">1,356</td><td align="center">2,521<xref rid="t2fn0001" ref-type="fn">
<sup>a</sup>
</xref></td></tr><tr><td align="left">Age, years, mean (SD)</td><td align="center">65.0 (9.4)</td><td align="center">62.4 (9.2)</td><td align="center">62.4 (8.2)</td><td align="center">63.5 (8.1)</td><td align="center">63.9 (8.8)</td><td align="center">63.2 (8.7)</td><td align="center">63.6 (8.7)</td><td align="center">63.4 (8.7)</td></tr><tr><td align="left">Male (%)</td><td align="center">52.0</td><td align="center">52.6</td><td align="center">68.5</td><td align="center">67.9</td><td align="center">54.3</td><td align="center">59.8</td><td align="center">60.0</td><td align="center">59.9</td></tr><tr><td align="left">Current smoker (%)</td><td align="center">44.5</td><td align="center">53.2</td><td align="center">53.9</td><td align="center">47.5</td><td align="center">50.9</td><td align="center">51.2</td><td align="center">49.3</td><td align="center">50.1</td></tr><tr><td align="left">Smoking history, pack-years, mean (SD)</td><td align="center">55.1 (28.4)</td><td align="center">53.4 (28.0)</td><td align="center">40.3 (19.8)</td><td align="center">39.7 (19.9)</td><td align="center">52.7 (27.3)</td><td align="center">47.9 (25.9)</td><td align="center">47.2 (25.1)</td><td align="center">47.5 (25.5)</td></tr><tr><td align="left">Post-bronchodilator FEV<sub>1</sub> (% predicted)</td><td align="center">54.4 (13.2)</td><td align="center">52.7 (13.3)</td><td align="center">56.4 (12.5)</td><td align="center">54.0 (13.2)</td><td align="center">52.8 (13.3)</td><td align="center">54.7 (13.3)</td><td align="center">53.6 (13.0)</td><td align="center">54.1 (13.2)</td></tr><tr><td colspan="9" align="left">COPD severity (GOLD stage) (%)</td></tr><tr><td align="left">&#x02003;Stage I (mild)</td><td align="center">0.0</td><td align="center">0.6</td><td align="center">0.0</td><td align="center">0.0</td><td align="center">0.3</td><td align="center">0.2</td><td align="center">0.1</td><td align="center">0.2</td></tr><tr><td align="left">&#x02003;Stage II (moderate)</td><td align="center">61.7</td><td align="center">53.8</td><td align="center">67.3</td><td align="center">59.2</td><td align="center">54.3</td><td align="center">59.9</td><td align="center">58.6</td><td align="center">59.2</td></tr><tr><td align="left">&#x02003;Stage III (severe)</td><td align="center">37.7</td><td align="center">45.7</td><td align="center">32.7</td><td align="center">40.6</td><td align="center">44.7</td><td align="center">39.5</td><td align="center">41.0</td><td align="center">40.3</td></tr><tr><td align="left">&#x02003;Stage IV (very severe)</td><td align="center">0.5</td><td align="center">0.0</td><td align="center">0.0</td><td align="center">0.2</td><td align="center">0.8</td><td align="center">0.4</td><td align="center">0.2</td><td align="center">0.3</td></tr><tr><td align="left">Patients with &#x02265;1 exacerbation prior to study entry (%)</td><td align="center">25.3</td><td align="center">24.0</td><td align="center">34.4</td><td align="center">36.4</td><td align="center">20.5</td><td align="center">26.4</td><td align="center">30.0</td><td align="center">28.3</td></tr><tr><td align="left">Patients with SGRQ total score &#x02265;25 (%)</td><td align="center">88.0</td><td align="center">88.9</td><td align="center">89.5</td><td align="center">88.2</td><td align="center">84.4</td><td align="center">87.0</td><td align="center">88.1</td><td align="center">87.5</td></tr></tbody></table><table-wrap-foot><fn id="t2fn0001"><p>
<sup>a</sup>Includes patients in the aclidinium 400&#x000a0;&#x003bc;g and placebo arms.</p></fn><fn><p>BID, twice-daily; COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>, forced expiratory volume in 1&#x000a0;second; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT, intent-to-treat; SD, standard deviation; SGRQ, St. George's Respiratory Questionnaire.</p></fn></table-wrap-foot></table-wrap>
<fig id="f0001" orientation="portrait" position="float"><label>Figure 1. </label><caption><p>Pooled analysis population, stratified by GOLD group (ITT population). <sup>a</sup>Patients had FEV<sub>1</sub> 30&#x02013;80% predicted. There were 62 patients with insufficient data for GOLD classification. ITT, intent-to-treat; GOLD, Global initiative for chronic Obstructive Lung Disease; <italic>N</italic>, number of patients in aclidinium 400&#x000a0;&#x003bc;g and placebo groups.</p></caption><graphic xlink:href="icop_a_1170111_f0001_b"/></fig>
<fig id="f0002" orientation="portrait" position="float"><label>Figure 2. </label><caption><p>Concomitant ICS use by study and overall (ITT population). ICS, inhaled corticosteroid; ITT, intent-to-treat; <italic>N</italic>, number of patients in aclidinium 400&#x000a0;&#x003bc;g and placebo groups.</p></caption><graphic xlink:href="icop_a_1170111_f0002_b"/></fig>
</p></sec><sec id="s0003-0002"><title>Number of exacerbations</title><p>In the pooled analysis, 12.5% of patients in the aclidinium group and 15.7% of patients in the placebo group had &#x02265;1 exacerbation of any severity; the odds of a patient experiencing &#x02265;1 exacerbation of any severity were reduced with aclidinium 400&#x000a0;&#x003bc;g versus placebo (odds ratio [OR]&#x000a0; = &#x000a0;0.78, <italic>p</italic>&#x000a0; = &#x000a0;0.039; <xref rid="t0003" ref-type="table">Table&#x000a0;3</xref>). In addition, in four of the five individual studies, the proportion of patients who experienced &#x02265;1 COPD exacerbation of any severity was greater in the placebo group than in the aclidinium group (<xref rid="t0003" ref-type="table">Table&#x000a0;3</xref>). Similarly, the proportion of patients who experienced &#x02265;1 moderate-to-severe exacerbation was numerically lower with aclidinium compared with placebo in each study; however, these results did not reach statistical significance at the study level or overall (<xref rid="t0003" ref-type="table">Table&#x000a0;3</xref>).
<table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3. </label><caption><p>Patients with &#x02265;1 exacerbation.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="70pt" align="left"/><col width="70pt" align="left"/><col width="70pt" align="left"/><col width="70pt" align="left"/><col width="70pt" align="left"/><col width="50pt" align="left"/><col width="50pt" align="left"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th colspan="3" align="center">Monotherapy<hr/></th><th colspan="2" align="center">Combination therapy<hr/></th><th align="center">&#x000a0;</th></tr><tr><th align="left">&#x000a0;</th><th colspan="2" align="center">3-month studies<hr/></th><th colspan="3" align="center">6-month studies<hr/></th><th align="center">&#x000a0;</th></tr><tr><th align="left">&#x000a0;</th><th align="center">ACCORD I</th><th align="center">ACCORD II</th><th align="center">ATTAIN</th><th align="center">ACLIFORM</th><th align="center">AUGMENT</th><th align="center">Overall</th></tr></thead><tbody><tr><td align="left">Number of patients</td><td align="center">375</td><td align="center">359</td><td align="center">542</td><td align="center">579<xref rid="t3fn0001" ref-type="fn">
<sup>a</sup>
</xref></td><td align="center">669<xref rid="t3fn0001" ref-type="fn">
<sup>a</sup>
</xref></td><td align="center">2,521<xref rid="t3fn0001" ref-type="fn">
<sup>a</sup>
</xref></td></tr><tr><td colspan="7" align="left">Patients with &#x02265;1 exacerbation of any severity, %</td></tr><tr><td align="left">&#x02003;Aclidinium 400&#x000a0;&#x003bc;g</td><td align="char" char=".">6.3</td><td align="char" char=".">10.7</td><td align="char" char=".">14.1</td><td align="char" char=".">10.9</td><td align="char" char=".">17.5</td><td align="char" char=".">12.5</td></tr><tr><td align="left">&#x02003;Placebo</td><td align="char" char=".">11.9</td><td align="char" char=".">10.4</td><td align="char" char=".">20.5</td><td align="char" char=".">13.4</td><td align="char" char=".">18.1</td><td align="char" char=".">15.7</td></tr><tr><td align="left">&#x02003;&#x02003;OR vs. placebo</td><td align="char" char=".">0.51</td><td align="char" char=".">0.95</td><td align="char" char=".">0.64</td><td align="char" char=".">0.78</td><td align="char" char=".">0.96</td><td align="char" char=".">0.78</td></tr><tr><td align="left">&#x02003;&#x02003;<italic>p</italic>-value</td><td align="char" char=".">0.073</td><td align="char" char=".">0.886</td><td align="char" char=".">0.051</td><td align="char" char=".">0.361</td><td align="char" char=".">0.848</td><td align="char" char=".">0.039</td></tr><tr><td colspan="7" align="left">Patients with &#x02265;1 moderate-to-severe exacerbation, %</td></tr><tr><td align="left">&#x02003;Aclidinium 400&#x000a0;&#x003bc;g</td><td align="char" char=".">5.8</td><td align="char" char=".">9.6</td><td align="char" char=".">12.3</td><td align="char" char=".">8.8</td><td align="char" char=".">15.7</td><td align="char" char=".">10.9</td></tr><tr><td align="left">&#x02003;Placebo</td><td align="char" char=".">8.6</td><td align="char" char=".">10.4</td><td align="char" char=".">16.1</td><td align="char" char=".">10.8</td><td align="char" char=".">16.6</td><td align="char" char=".">13.3</td></tr><tr><td align="left">&#x02003;&#x02003;OR vs. placebo</td><td align="char" char=".">0.65</td><td align="char" char=".">0.82</td><td align="char" char=".">0.73</td><td align="char" char=".">0.79</td><td align="char" char=".">0.94</td><td align="char" char=".">0.82</td></tr><tr><td align="left">&#x02003;&#x02003;<italic>p</italic>-value</td><td align="char" char=".">0.292</td><td align="char" char=".">0.584</td><td align="char" char=".">0.206</td><td align="char" char=".">0.423</td><td align="char" char=".">0.768</td><td align="char" char=".">0.116</td></tr></tbody></table><table-wrap-foot><fn id="t3fn0001"><p>
<sup>a</sup>Exacerbations analyses from the individual ACLIFORM and AUGMENT studies are reported for the ITT-exacerbations populations (579 and 669 patients, respectively; all patients who received at least one dose of the study medication), as specified in the study protocols and published previously (<xref rid="cit0020" ref-type="bibr">20,32</xref>); pooled analyses include data from the ITT populations (577 and 668 patients, respectively; all patients who received at least one dose of the study medication and had a baseline and &#x02265;1 post-baseline FEV<sub>1</sub> assessment) for consistency with the ACCORD I, ACCORD II and ATTAIN study populations.</p></fn><fn><p>ITT, intent-to-treat; OR, odds ratio</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="s0003-0003"><title>Rate of exacerbations</title><p>In the pooled data, aclidinium reduced the rate of exacerbations of any severity compared with placebo (rate ratio [RR]&#x000a0; = &#x000a0;0.79, <italic>p</italic>&#x000a0; = &#x000a0;0.026; <xref rid="f0003" ref-type="fig">Figure&#x000a0;3A</xref>). By GOLD group, the reduction in the rate of exacerbations with aclidinium compared with placebo was greatest in GOLD Groups B and D (<xref rid="f0003" ref-type="fig">Figure&#x000a0;3B</xref>) and a rate reduction was also observed with aclidinium in GOLD Group D and GOLD Group B+D (Group D: RR&#x000a0; = &#x000a0;0.76, <italic>p</italic>&#x000a0; = &#x000a0;0.052; Group B+D: RR&#x000a0; = &#x000a0;0.78, <italic>p</italic>&#x000a0; = &#x000a0;0.025; <xref rid="f0003" ref-type="fig">Figure&#x000a0;3B</xref>). Results for Groups A and C are not shown individually due to the low number of patients and non-convergence of the statistical model. Additionally, the rate of exacerbations of any severity was very low in Groups A and C (placebo: 0.20 and 0.05 exacerbations per patient per year, respectively) compared with Groups B and D (placebo: 0.44 and 0.74 exacerbations per patient per year, respectively).
<fig id="f0003" orientation="portrait" position="float"><label>Figure 3. </label><caption><p>Rate of COPD exacerbations of any severity (A) overall (individual studies and pooled analyses)<sup>a</sup> and (B) stratified by GOLD group (pooled analysis). <sup>a</sup>Exacerbations analyses from the individual ACLIFORM and AUGMENT studies are reported for the ITT-exacerbations populations of the aclidinium monotherapy and placebo arms only (579 and 669 patients, respectively; all patients who received at least one dose of the study medication), as specified in the study protocols and published previously (<xref rid="cit0020" ref-type="bibr">20,32</xref>); pooled analyses include data from the ITT populations (577 and 668 patients, respectively; all patients who received at least one dose of the study medication and had a baseline and &#x02265;1 post-baseline FEV<sub>1</sub> assessment) for consistency with the ACCORD I, ACCORD II and ATTAIN study populations. Percentages are the proportion of all GOLD-classified patients (<italic>N</italic>&#x000a0; = &#x000a0;2,459) in each GOLD group. CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT, intent-to-treat; RR, rate ratio; <italic>N</italic>, number of patients in aclidinium 400&#x000a0;&#x003bc;g and placebo groups.</p></caption><graphic xlink:href="icop_a_1170111_f0003_b"/></fig>
</p><p>The data for moderate-to-severe exacerbations followed a similar pattern to the data for exacerbations of any severity, with a reduction in exacerbation rate with aclidinium compared with placebo (RR&#x000a0; = &#x000a0;0.80, <italic>p</italic>&#x000a0; = &#x000a0;0.044; <xref rid="f0004" ref-type="fig">Figure&#x000a0;4A</xref>). <xref rid="f0004" ref-type="fig">Figure&#x000a0;4B</xref> presents data for the rate of moderate-to-severe exacerbations stratified by GOLD group. The reduction in rate of moderate-to-severe exacerbations with aclidinium versus placebo was greatest in GOLD Group D (RR&#x000a0; = &#x000a0;0.73, <italic>p</italic>&#x000a0; = &#x000a0;0.045) and there was a reduction in GOLD Group B+D (RR&#x000a0; = &#x000a0;0.78, <italic>p</italic>&#x000a0; = &#x000a0;0.031). Again, the data for Groups A and C are not presented individually for the reasons stated above. The rate of moderate-to-severe exacerbations in Groups B and D was higher than in Groups A and C (placebo rates: 0.38 and 0.63 exacerbations per patient per year vs. 0.10 and 0.01 exacerbations per patient per year, respectively).
<fig id="f0004" orientation="portrait" position="float"><label>Figure 4. </label><caption><p>Rate of moderate-to-severe COPD exacerbations (A) overall (individual studies and pooled analyses)<sup>a</sup> and (B) stratified by GOLD group (pooled analysis). <sup>a</sup>Exacerbations analyses from the individual ACLIFORM and AUGMENT studies are reported for the ITT-exacerbations populations of the aclidinium monotherapy and placebo arms only (579 and 669 patients, respectively; all patients who received at least one dose of the study medication), as specified in the study protocols and published previously (<xref rid="cit0020" ref-type="bibr">20,32</xref>); pooled analyses include data from the ITT populations (577 and 668 patients, respectively; all patients who received at least one dose of the study medication and had a baseline and &#x02265;1 post-baseline FEV<sub>1</sub> assessment) for consistency with the ACCORD I, ACCORD II and ATTAIN study populations. Percentages are the proportion of all GOLD-classified patients (<italic>N</italic>&#x000a0; = &#x000a0;2,459) in each GOLD group. CI, confidence interval; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT, intent-to-treat; RR, rate ratio; <italic>N</italic>, number of patients in aclidinium 400&#x000a0;&#x003bc;g and placebo groups.</p></caption><graphic xlink:href="icop_a_1170111_f0004_b"/></fig>
</p><p>When stratified by concomitant ICS use, exacerbation rates were numerically higher in patients who were using ICS compared with those who were not using ICS (<xref rid="t0004" ref-type="table">Table&#x000a0;4</xref>). In addition, there was a reduction in exacerbation rate with aclidinium 400&#x000a0;&#x003bc;g versus placebo for exacerbations of any severity (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.026) and moderate-to-severe exacerbations in the overall patient group (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.044), but not those with concomitant ICS use or those without concomitant ICS use when considered separately (<xref rid="t0004" ref-type="table">Table&#x000a0;4</xref>).
<table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4. </label><caption><p>Exacerbation rates stratified by concomitant ICS use (ITT population).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt" align="left"/><col width="30pt" align="left"/><col width="30pt" align="left"/><col width="30pt" align="left"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th align="center">Overall</th><th align="center">ICS</th><th align="center">No ICS</th></tr></thead><tbody><tr><td colspan="4" align="left">Rate of exacerbations of any severity (per patient per year)</td></tr><tr><td align="left">&#x02003;Aclidinium 400&#x000a0;&#x003bc;g, <italic>N</italic>&#x000a0; = &#x000a0;1,356</td><td align="center">0.41</td><td align="char" char=".">0.54</td><td align="char" char=".">0.32</td></tr><tr><td align="left">&#x02003;Placebo, <italic>N</italic>&#x000a0; = &#x000a0;1,165</td><td align="char" char=".">0.52</td><td align="char" char=".">0.67</td><td align="char" char=".">0.42</td></tr><tr><td align="left">&#x02003;RR vs. placebo</td><td align="char" char=".">0.79</td><td align="char" char=".">0.80</td><td align="char" char=".">0.77</td></tr><tr><td align="left">&#x02003;<italic>p</italic>-value</td><td align="char" char=".">0.026</td><td align="char" char=".">0.117</td><td align="char" char=".">0.090</td></tr><tr><td colspan="4" align="left">Rate of moderate-to-severe exacerbations (per patient per year)</td></tr><tr><td align="left">&#x02003;Aclidinium 400&#x000a0;&#x003bc;g, <italic>N</italic>&#x000a0; = &#x000a0;1,356</td><td align="char" char=".">0.35</td><td align="char" char=".">0.46</td><td align="char" char=".">0.27</td></tr><tr><td align="left">&#x02003;Placebo, <italic>N</italic>&#x000a0; = &#x000a0;1,165</td><td align="char" char=".">0.44</td><td align="char" char=".">0.57</td><td align="char" char=".">0.35</td></tr><tr><td align="left">&#x02003;RR vs. placebo</td><td align="char" char=".">0.80</td><td align="char" char=".">0.82</td><td align="char" char=".">0.76</td></tr><tr><td align="left">&#x02003;<italic>p</italic>-value</td><td align="char" char=".">0.044</td><td align="char" char=".">0.194</td><td align="char" char=".">0.117</td></tr></tbody></table><table-wrap-foot><fn><p>ICS, inhaled corticosteroid; ITT, intent-to-treat; <italic>N</italic>, number of patients; RR, rate ratio.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="s0003-0004"><title>Time to first exacerbation</title><p>Aclidinium increased the time to first exacerbation of any severity compared with placebo overall (hazard ratio [HR]&#x000a0; = &#x000a0;0.79, <italic>p</italic>&#x000a0; = &#x000a0;0.026; <xref rid="f0005" ref-type="fig">Figure&#x000a0;5A</xref>) and for patients in GOLD Group B+D (HR&#x000a0; = &#x000a0;0.79, <italic>p</italic>&#x000a0; = &#x000a0;0.031; <xref rid="f0005" ref-type="fig">Figure&#x000a0;5C</xref>) but not GOLD Group&#x000a0;A+C (HR&#x000a0; = &#x000a0;0.99, <italic>p</italic>&#x000a0; = &#x000a0;0.972; <xref rid="f0005" ref-type="fig">Figure&#x000a0;5B</xref>). The changes in time to first moderate-to-severe exacerbation with aclidinium versus placebo followed a similar pattern (all patients: HR&#x000a0; = &#x000a0;0.82, <italic>p</italic>&#x000a0; = &#x000a0;0.081; Group B+D: HR&#x000a0; = &#x000a0;0.81, <italic>p</italic>&#x000a0; = &#x000a0;0.073; Group A+C: HR&#x000a0; = &#x000a0;1.37, <italic>p</italic>&#x000a0; = &#x000a0;0.511).
<fig id="f0005" orientation="portrait" position="float"><label>Figure 5. </label><caption><p>Time to first COPD exacerbation of any severity in (A) all patients; (B) patients in GOLD Groups A and C; and (C) patients in GOLD Groups B and D (ITT population). COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; HR, hazard ratio; ITT, intent-to-treat; <italic>N</italic>, number of patients.</p></caption><graphic xlink:href="icop_a_1170111_f0005_b"/></fig>
</p></sec></sec><sec sec-type="discussion" id="s0004"><title>Discussion</title><p>This pooled analysis shows that aclidinium 400&#x000a0;&#x003bc;g BID reduces the frequency of exacerbations in patients with COPD with moderate-to-severe airflow limitation. Specifically, the number of exacerbations of any severity was reduced with aclidinium compared with placebo (<italic>p</italic>&#x000a0; = &#x000a0;0.039), as was the annual rate of both moderate-to-severe exacerbations (<italic>p</italic>&#x000a0; = &#x000a0;0.044) and exacerbations of any severity (<italic>p</italic>&#x000a0; = &#x000a0;0.026). Additionally, aclidinium 400&#x000a0;&#x003bc;g delayed the time to first exacerbation of any severity in all patients (<italic>p</italic>&#x000a0; = &#x000a0;0.026); however, the delay in the time to first moderate-to-severe exacerbation did not reach statistical significance. Finally, the reduction in exacerbation frequency was most apparent in GOLD Groups B and D (i.e. patients with more symptoms), although it should be noted that patient numbers in Groups A and C were low (10.7% of the total population).</p><p>In this pooled analysis, aclidinium 400&#x000a0;&#x003bc;g reduced the rate of exacerbations of any severity and moderate-to-severe exacerbations by approximately 20% compared with placebo. These results are consistent with recent studies of other LAMAs. For example, the 26-week GLOW 1 study and the 52-week GLOW 2 study demonstrated reduced rates of exacerbations of 28&#x02013;34% with glycopyrrolate 50&#x000a0;&#x003bc;g once daily (QD) versus placebo <xref rid="cit0013" ref-type="bibr">(13)</xref>. The 4-year UPLIFT trial showed a 14% reduction in rate of exacerbations with tiotropium 18&#x000a0;&#x003bc;g QD versus placebo (although it should be noted that LABAs and ICS were allowed as concomitant medication) <xref rid="cit0012" ref-type="bibr">(12)</xref>, in contrast to most short-term studies. Similar to the GLOW and UPLIFT studies, our study populations were not enriched for exacerbations, and although reductions in the rate of exacerbations were observed with aclidinium versus placebo, treatment effects may be greater in a population with a history of exacerbations. Indeed, the highest rates of exacerbation were observed in symptomatic patients (GOLD Groups B and D) and it was these patients who displayed the largest reductions in exacerbation rates with aclidinium versus placebo. The 1-year MISTRAL study included a patient population enriched for exacerbations and found a 35% reduction in rate of exacerbations with tiotropium 18&#x000a0;&#x003bc;g QD versus placebo <xref rid="cit0025" ref-type="bibr">(25)</xref>. Greater reductions in exacerbation rates have also been demonstrated with LAMAs compared with LABAs in patient populations enriched for exacerbations (<xref rid="cit0014" ref-type="bibr">14,15</xref>). Similarly, in the present analysis, aclidinium significantly reduced exacerbations of any severity in patients with concomitant ICS use but not patients without concomitant ICS use, and this may be due to the higher exacerbation rate in patients who are prescribed ICS.</p><p>In addition to the effects on exacerbation rates,<xref rid="t0004" ref-type="table">
<sup>Table 4</sup>
</xref>
<xref rid="f0005" ref-type="fig">
<sup>Figure 5</sup>
</xref> we observed a delay in time to first exacerbation of any severity with aclidinium versus placebo and a delay in time to first moderate-to-severe exacerbation. Again, these results are consistent with previous studies with other LAMAs (<xref rid="cit0012" ref-type="bibr">12,13</xref>); however, it should be noted that comparing the treatment effects in our pooled analysis with those observed in other studies can be problematic due to major differences in study design (e.g. differences in patient population, treatment duration, allowed concomitant medications and exacerbation endpoints).</p><p>Investigating the effects of treatment on exacerbations according to the new GOLD classification may be useful for identifying differences in response in different GOLD groups and thus predicting which patients will respond better to a particular therapy. However, our sub-group analysis is limited by the low patient numbers and rate of exacerbations in GOLD Groups A and C. The distribution of patients across GOLD groups will depend on the methods used for GOLD classification (i.e. modified Medical Research Council vs. COPD Assessment Test vs. SGRQ and airflow limitation vs. exacerbation history vs. both) (<xref rid="cit0026" ref-type="bibr">26&#x02013;29</xref>). The COPDgene study used the same classification parameters (SGRQ, airflow limitation and exacerbation history) as our pooled analysis and reported a higher proportion of patients in Group A (29.4% vs. 8.1%), a lower proportion in Group B (24.7% vs. 47.9%) and a similar proportion in Groups C (4.9% vs. 2.6%) and D (41.0% vs. 41.4%) <xref rid="cit0023" ref-type="bibr">(23)</xref>. These results suggest that a greater proportion of patients had an SGRQ score &#x02265;25 in our pooled analysis compared with the COPDgene study, possibly a consequence of different inclusion criteria (patients with moderate-to-severe vs. any severity of airflow limitation) or geographical variations in SGRQ due to real or perceived differences in health status (our pooled analysis included study sites in North America, Europe, Africa and the Asia-Pacific region; the COPDgene study was conducted in North America) <xref rid="cit0023" ref-type="bibr">(23)</xref>.</p><p>The mechanisms by which LAMAs may help prevent COPD exacerbations are not well understood <xref rid="cit0030" ref-type="bibr">(30)</xref>. Various mechanisms have been proposed, including improved lung mechanics and bronchodilation, reduced lung hyperinflation, reduced airway resistance, improved inspiratory capacity, reduced sputum production, inhibition of viral activity in the lung, and direct and indirect effects on lung inflammation <xref rid="cit0030" ref-type="bibr">(30)</xref>.</p><p>Pooling of data from studies with similar designs can confirm trends that are observed/reveal trends that may not be evident in the individual studies, particularly when the event rate is low. In this analysis, pooling of data gave a sufficient number of patients in each GOLD group for exploratory sub-group analyses.</p><p>One potential limitation of this pooled analysis is the relatively short duration of the five studies. However, a recent systematic review of tiotropium versus placebo showed similar reductions in exacerbation rates in studies of &#x0003c;1&#x000a0;year (13 studies of 3&#x02013;6&#x000a0;months and one study of 9&#x000a0;months) and studies of &#x02265;1&#x000a0;year (six studies of 1&#x000a0;year, one study of 2&#x000a0;years and one study of 4&#x000a0;years) <xref rid="cit0031" ref-type="bibr">(31)</xref>, suggesting that shorter studies can still provide reliable estimates of treatment effect. Another potential limitation is the use of SGRQ for segregating GOLD classification groups as GOLD only uses the modified Medical Research Council dyspnoea scale, COPD assessment test or Clinical COPD Questionnaire<xref rid="f0005" ref-type="fig">
<sup>Figure 5</sup>
</xref> for this purpose <xref rid="cit0011" ref-type="bibr">(11)</xref>.</p></sec><sec sec-type="conclusions" id="s0005"><title>Conclusions</title><p>The results of this pooled analysis add to the growing body of evidence that the use of a LAMA as maintenance therapy can help prevent exacerbations of COPD by demonstrating an effect within a relatively short period of time (3&#x02013;6&#x000a0;months). In a population of patients with COPD that is not enriched for exacerbations, aclidinium 400&#x000a0;&#x003bc;g BID may reduce the frequency of exacerbations by approximately 20% compared with placebo. The treatment effect may have been greater in symptomatic patients because these patients had higher rates of exacerbation compared with non-symptomatic patients and reductions in rate are more likely to be observed in patients with more frequent exacerbations.</p></sec><sec id="s0006"><title>Declaration of interest</title><p>This pooled analysis was funded by Almirall S.A., Barcelona, Spain. Almirall S.A. designed and conducted the pooled analysis and reviewed the data. Almirall S.A. and AstraZeneca PLC were involved in review of the manuscript. Suzanne McAllister, PhD, and Richard Knight, PhD, of Complete Medical Communications (Macclesfield, UK), provided medical writing support funded by AstraZeneca PLC, Barcelona, Spain.</p><p>JAW has received research grants from GSK, Takeda, Almirall, Novartis, Johnson &#x00026; Johnson and Vifor Pharma; honoraria for advisory boards and/or lectures from Almirall, Novartis, GSK, Boehringer Ingelheim, Takeda, Johnson &#x00026; Johnson, Vifor Pharma, Napp, Pfizer and AstraZeneca. AA has received research grants from Almirall, AstraZeneca, GSK, Menarini and MSD as well as honoraria for lectures or advisory boards from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini, Novartis, Teva, Kyorin, Glenmark and Takeda. GD has received honoraria for advisory boards for Almirall and lecture fees from Micom SPr. FC is an employee of AstraZeneca PLC, Barcelona, Spain and former employee of Almirall S.A., Barcelona, Spain. RL is an employee of AstraZeneca PLC, Barcelona, Spain, and former employee of Almirall S.A., Barcelona, Spain. EGG is an employee of AstraZeneca PLC, Barcelona, Spain and former employee of Almirall S.A., Barcelona, Spain.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank the study investigators at each of the participating centers for their contribution to the studies.</p></ack><sec><fn-group content-type="endnotes"><title>Endnote</title><fn id="en0001"><label>1. </label><p>Registered trademark of AstraZeneca group of companies; for use within the USA as Pressair&#x000ae; and as Genuair&#x02122; within all other licensed territories.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="cit0001"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>Thomas</surname><given-names>NE</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Jenkins</surname><given-names>CR</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name></person-group>
<article-title>Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study</article-title>
<source>Am J Respir Crit Care Med</source>
<year>2008</year>
<volume>178</volume>
<fpage>332</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="pmid">18511702</pub-id></element-citation></ref><ref id="cit0002"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Seemungal</surname><given-names>TA</given-names></name><name><surname>Bhowmik</surname><given-names>A</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group>
<article-title>Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease</article-title>
<source>Thorax</source>
<year>2002</year>
<volume>57</volume>
<fpage>847</fpage>
<lpage>852</lpage>
<pub-id pub-id-type="pmid">12324669</pub-id></element-citation></ref><ref id="cit0003"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanner</surname><given-names>RE</given-names></name><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name></person-group>
<article-title>Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study</article-title>
<source>Am J Respir Crit Care Med</source>
<year>2001</year>
<volume>164</volume>
<fpage>358</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="pmid">11500333</pub-id></element-citation></ref><ref id="cit0004"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Bakke</surname><given-names>P</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name></person-group>
<article-title>Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team</article-title>
<source>Am J Respir Crit Care Med</source>
<year>2014</year>
<volume>189</volume>
<fpage>1022</fpage>
<lpage>1030</lpage>
<pub-id pub-id-type="pmid">24552242</pub-id></element-citation></ref><ref id="cit0005"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Lamarca</surname><given-names>R</given-names></name><name><surname>Chuecos</surname><given-names>F</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name></person-group>
<article-title>Characterisation and impact of reported and unreported exacerbations: results from ATTAIN</article-title>
<source>Eur Respir J</source>
<year>2014</year>
<volume>44</volume>
<fpage>1156</fpage>
<lpage>1165</lpage>
<pub-id pub-id-type="pmid">25234803</pub-id></element-citation></ref><ref id="cit0006"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seemungal</surname><given-names>TA</given-names></name><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Paul</surname><given-names>EA</given-names></name><name><surname>Bestall</surname><given-names>JC</given-names></name><name><surname>Jeffries</surname><given-names>DJ</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group>
<article-title>Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease</article-title>
<source>Am J Respir Crit Care Med</source>
<year>1998</year>
<volume>157</volume>
<fpage>1418</fpage>
<lpage>1422</lpage>
<pub-id pub-id-type="pmid">9603117</pub-id></element-citation></ref><ref id="cit0007"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Shapiro</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group>
<article-title>Negative impacts of unreported COPD exacerbations on health-related quality of life at 1&#x000a0;year</article-title>
<source>Eur Respir J</source>
<year>2010</year>
<volume>35</volume>
<fpage>1022</fpage>
<lpage>1030</lpage>
<pub-id pub-id-type="pmid">19897555</pub-id></element-citation></ref><ref id="cit0008"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soler-Cataluna</surname><given-names>JJ</given-names></name><name><surname>Martinez-Garcia</surname><given-names>MA</given-names></name><name><surname>Roman</surname><given-names>SP</given-names></name><name><surname>Salcedo</surname><given-names>E</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Ochando</surname><given-names>R</given-names></name></person-group>
<article-title>Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease</article-title>
<source>Thorax</source>
<year>2005</year>
<volume>60</volume>
<fpage>925</fpage>
<lpage>931</lpage>
<pub-id pub-id-type="pmid">16055622</pub-id></element-citation></ref><ref id="cit0009"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wouters</surname><given-names>EF.</given-names></name></person-group>
<article-title>Economic analysis of the confronting COPD survey: an overview of results</article-title>
<source>Respir Med</source>
<year>2003</year>
<volume>97</volume>
<issue>Suppl C</issue>
<fpage>S3</fpage>
<lpage>S14</lpage>
</element-citation></ref><ref id="cit0010"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Garcia-Polo</surname><given-names>C</given-names></name><name><surname>Domenech</surname><given-names>A</given-names></name><name><surname>Villegas</surname><given-names>G</given-names></name><name><surname>Conget</surname><given-names>F</given-names></name><name><surname>de la Roza</surname><given-names>C</given-names></name></person-group>
<article-title>Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease</article-title>
<source>Lung</source>
<year>2013</year>
<volume>191</volume>
<fpage>523</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="pmid">23842641</pub-id></element-citation></ref><ref id="cit0011"><element-citation publication-type="web">
<person-group person-group-type="author"><collab>Global Initiative for Chronic Obstructive Lung Disease</collab></person-group>
<article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]</article-title>
<ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdf">http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdf</ext-link>
</element-citation></ref><ref id="cit0012"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Senn</surname><given-names>S</given-names></name><name><surname>Burkhart</surname><given-names>D</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name><name><surname>Menjoge</surname><given-names>S</given-names></name></person-group>
<article-title>A 4-year trial of tiotropium in chronic obstructive pulmonary disease</article-title>
<source>N Engl J Med</source>
<year>2008</year>
<volume>359</volume>
<fpage>1543</fpage>
<lpage>1554</lpage>
<pub-id pub-id-type="pmid">18836213</pub-id></element-citation></ref><ref id="cit0013"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Banerji</surname><given-names>D</given-names></name></person-group>
<article-title>Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>
<year>2012</year>
<volume>7</volume>
<fpage>729</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="pmid">23118536</pub-id></element-citation></ref><ref id="cit0014"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Decramer</surname><given-names>ML</given-names></name><name><surname>Chapman</surname><given-names>KR</given-names></name><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Frith</surname><given-names>P</given-names></name><name><surname>Devouassoux</surname><given-names>G</given-names></name><name><surname>Fritscher</surname><given-names>C</given-names></name></person-group>
<article-title>Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study</article-title>
<source>Lancet Respir Med</source>
<year>2013</year>
<volume>1</volume>
<fpage>524</fpage>
<lpage>533</lpage>
<pub-id pub-id-type="pmid">24461613</pub-id></element-citation></ref><ref id="cit0015"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vogelmeier</surname><given-names>C</given-names></name><name><surname>Hederer</surname><given-names>B</given-names></name><name><surname>Glaab</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Rutten-van Molken</surname><given-names>MPMH</given-names></name><name><surname>Beeh</surname><given-names>KM</given-names></name></person-group>
<article-title>Tiotropium versus salmeterol for the prevention of exacerbations of COPD</article-title>
<source>N Engl J Med</source>
<year>2011</year>
<volume>364</volume>
<fpage>1093</fpage>
<lpage>1103</lpage>
<pub-id pub-id-type="pmid">21428765</pub-id></element-citation></ref><ref id="cit0016"><element-citation publication-type="web">
<person-group person-group-type="author"><name><surname>AstraZeneca</surname><given-names>PLC.</given-names></name></person-group>
<article-title>Summary of product characteristics Eklira Genuair 322 &#x003bc;g inhalation powder [Internet]</article-title>
<ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/27001/">http://www.medicines.org.uk/emc/medicine/27001/</ext-link>
</element-citation></ref><ref id="cit0017"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Lamarca</surname><given-names>R</given-names></name><name><surname>de Miquel</surname><given-names>G</given-names></name></person-group>
<article-title>Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study</article-title>
<source>Eur Respir J</source>
<year>2012</year>
<volume>40</volume>
<fpage>830</fpage>
<lpage>836</lpage>
<pub-id pub-id-type="pmid">22441743</pub-id></element-citation></ref><ref id="cit0018"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kerwin</surname><given-names>EM</given-names></name><name><surname>D'Urzo</surname><given-names>AD</given-names></name><name><surname>Gelb</surname><given-names>AF</given-names></name><name><surname>Lakkis</surname><given-names>H</given-names></name><name><surname>Garcia Gil</surname><given-names>E</given-names></name><name><surname>Caracta</surname><given-names>CF</given-names></name></person-group>
<article-title>Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)</article-title>
<source>COPD</source>
<year>2012</year>
<volume>9</volume>
<fpage>90</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">22320148</pub-id></element-citation></ref><ref id="cit0019"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rennard</surname><given-names>SI</given-names></name><name><surname>Scanlon</surname><given-names>PD</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Rekeda</surname><given-names>L</given-names></name><name><surname>Maurer</surname><given-names>BT</given-names></name><name><surname>Garcia Gil</surname><given-names>E</given-names></name></person-group>
<article-title>ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients</article-title>
<source>Clin Drug Investig</source>
<year>2013</year>
<volume>33</volume>
<fpage>893</fpage>
<lpage>904</lpage>
</element-citation></ref><ref id="cit0020"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Korn</surname><given-names>S</given-names></name><name><surname>Serra</surname><given-names>C</given-names></name><name><surname>Molins</surname><given-names>E</given-names></name></person-group>
<article-title>Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study</article-title>
<source>BMC Pulm Med</source>
<year>2014</year>
<volume>14</volume>
<fpage>178</fpage>
<pub-id pub-id-type="pmid">25404569</pub-id></element-citation></ref><ref id="cit0021"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bateman</surname><given-names>E</given-names></name><name><surname>Rennard</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Molins</surname><given-names>E</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Leselbaum</surname><given-names>A</given-names></name></person-group>
<article-title>Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies</article-title>
<source>Eur Respir J</source>
<year>2014</year>
<volume>44</volume>
<fpage>285</fpage>
</element-citation></ref><ref id="cit0022"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D'Urzo</surname><given-names>AD</given-names></name><name><surname>Rennard</surname><given-names>SI</given-names></name><name><surname>Kerwin</surname><given-names>EM</given-names></name><name><surname>Mergel</surname><given-names>V</given-names></name><name><surname>Leselbaum</surname><given-names>AR</given-names></name><name><surname>Caracta</surname><given-names>CF</given-names></name></person-group>
<article-title>Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study</article-title>
<source>Respir Res</source>
<year>2014</year>
<volume>15</volume>
<fpage>123</fpage>
<pub-id pub-id-type="pmid">25756831</pub-id></element-citation></ref><ref id="cit0023"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>MK</given-names></name><name><surname>Muellerova</surname><given-names>H</given-names></name><name><surname>Curran-Everett</surname><given-names>D</given-names></name><name><surname>Dransfield</surname><given-names>MT</given-names></name><name><surname>Washko</surname><given-names>GR</given-names></name><name><surname>Regan</surname><given-names>EA</given-names></name></person-group>
<article-title>GOLD 2011 disease severity classification in COPDGene: a prospective cohort study</article-title>
<source>Lancet Respir Med</source>
<year>2013</year>
<volume>1</volume>
<fpage>43</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">24321803</pub-id></element-citation></ref><ref id="cit0024"><element-citation publication-type="web">
<person-group person-group-type="author"><collab>Global Initiative for Chronic Obstructive Lung Disease</collab></person-group>
<article-title>Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [Internet]</article-title>
<ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.com/guidelines-global-strategy-for-diagnosis-management.html">http://www.goldcopd.com/guidelines-global-strategy-for-diagnosis-management.html</ext-link>
</element-citation></ref><ref id="cit0025"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dusser</surname><given-names>D</given-names></name><name><surname>Bravo</surname><given-names>ML</given-names></name><name><surname>Iacono</surname><given-names>P</given-names></name></person-group>
<article-title>The effect of tiotropium on exacerbations and airflow in patients with COPD</article-title>
<source>Eur Respir J</source>
<year>2006</year>
<volume>27</volume>
<fpage>547</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="pmid">16507855</pub-id></element-citation></ref><ref id="cit0026"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zogg</surname><given-names>S</given-names></name><name><surname>Durr</surname><given-names>S</given-names></name><name><surname>Miedinger</surname><given-names>D</given-names></name><name><surname>Steveling</surname><given-names>EH</given-names></name><name><surname>Maier</surname><given-names>S</given-names></name><name><surname>Leuppi</surname><given-names>JD</given-names></name></person-group>
<article-title>Differences in classification of COPD patients into risk groups A-D: a cross-sectional study</article-title>
<source>BMC Res Notes</source>
<year>2014</year>
<volume>7</volume>
<fpage>562</fpage>
<pub-id pub-id-type="pmid">25148698</pub-id></element-citation></ref><ref id="cit0027"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Ban</surname><given-names>HJ</given-names></name><name><surname>Kwon</surname><given-names>YS</given-names></name><name><surname>Oh</surname><given-names>IJ</given-names></name></person-group>
<article-title>Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses</article-title>
<source>BMC Pulm Med</source>
<year>2013</year>
<volume>13</volume>
<fpage>35</fpage>
<pub-id pub-id-type="pmid">23731868</pub-id></element-citation></ref><ref id="cit0028"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holt</surname><given-names>S</given-names></name><name><surname>Sheahan</surname><given-names>D</given-names></name><name><surname>Helm</surname><given-names>C</given-names></name><name><surname>Tofield</surname><given-names>C</given-names></name><name><surname>Corin</surname><given-names>A</given-names></name><name><surname>Kocks</surname><given-names>JW</given-names></name></person-group>
<article-title>Little agreement in GOLD category using CAT and mMRC in 450 primary care COPD patients in New Zealand</article-title>
<source>NPJ Prim Care Respir Med</source>
<year>2014</year>
<volume>24</volume>
<fpage>14025</fpage>
<pub-id pub-id-type="pmid">25056446</pub-id></element-citation></ref><ref id="cit0029"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Martinez</surname><given-names>F</given-names></name><name><surname>Vogelmeier</surname><given-names>C</given-names></name></person-group>
<article-title>FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts</article-title>
<source>Eur Respir J</source>
<year>2013</year>
<volume>42</volume>
<fpage>1391</fpage>
<lpage>1401</lpage>
<pub-id pub-id-type="pmid">23645406</pub-id></element-citation></ref><ref id="cit0030"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Seemungal</surname><given-names>TA</given-names></name></person-group>
<article-title>The role of bronchodilator treatment in the prevention of exacerbations of COPD</article-title>
<source>Eur Respir J</source>
<year>2012</year>
<volume>40</volume>
<fpage>1545</fpage>
<lpage>1554</lpage>
<pub-id pub-id-type="pmid">22835613</pub-id></element-citation></ref><ref id="cit0031"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karner</surname><given-names>C</given-names></name><name><surname>Chong</surname><given-names>J</given-names></name><name><surname>Poole</surname><given-names>P</given-names></name></person-group>
<article-title>Tiotropium versus placebo for chronic obstructive pulmonary disease</article-title>
<source>Cochrane Database Syst Rev</source>
<year>2012</year>
<volume>7</volume>
<fpage>CD009285</fpage>
</element-citation></ref><ref id="cit0032"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Chapman</surname><given-names>KR</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>D'Urzo</surname><given-names>AD</given-names></name><name><surname>Molins</surname><given-names>E</given-names></name><name><surname>Leselbaum</surname><given-names>A</given-names></name></person-group>
<article-title>Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)</article-title>
<source>Respir Res</source>
<year>2015</year>
<volume>16</volume>
<fpage>92</fpage>
<pub-id pub-id-type="pmid">26233481</pub-id></element-citation></ref></ref-list></back></article>